ExploreWatchlistsPricing
  1. JP-listed companies
  2. kainos loboratories,inc
  3. Financials
  4. Stockholders' equity

kainos loboratories,inc (4556)

Market cap
¥10.4B
P/E ratio
16x
Kainos manufactures diagnostic pharmaceuticals, laboratory reagents, and medical devices for hospitals and research facilities to improve healthcare quality.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20267,238+6.83%
Mar 31, 20256,775+8.12%
Mar 31, 20246,266+10.52%
Mar 31, 20235,670+9.03%
Mar 31, 20225,200+11.60%
Mar 31, 20214,660+6.35%
Mar 31, 20204,381+20.52%
Mar 31, 20193,635-5.70%
Mar 31, 20183,855+5.82%
Mar 31, 20173,643+8.75%
Mar 31, 20163,350+2.01%
Mar 31, 20153,284+6.85%
Mar 31, 20143,073

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat